TNFSF13B and lobular neoplasia: Targeted therapies aiming to reduce pathogenic autoantibody production (e.g., anti-CD20 monoclonal antibodies, anti-BAFF agents, type I IFN receptor blockade and IFN signaling inhibition) are increasingly used in refractory or relapsing LN, further highlighting the central role of humoral autoimmunity in disease pathogenesis [119,120].